trending Market Intelligence /marketintelligence/en/news-insights/trending/Jh7P0b5bRflKiXuNRr5UDQ2 content esgSubNav
In This List

Cesca Therapeutics acquires complete ownership of ThermoGenesis unit

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Cesca Therapeutics acquires complete ownership of ThermoGenesis unit

Cesca Therapeutics Inc. acquired the remaining 20% stake in its subsidiary ThermoGenesis Corp. from Bay City Capital LLC, an asset management company that invests in biopharmaceuticals, drug discovery and research tools.

In exchange, Rancho Cordova, Calif.-based Cesca Therapeutics has granted Bay City Capital 20% ownership in CARTXpress Bio Inc., a newly created subsidiary of ThermoGenesis.

ThermoGenesis will keep the remaining 80% stake in CARTXpress Bio, which will focus on the manufacturing CAR-T cell therapies for cancer using the automated CAR-TXpress system.

CAR-T cell therapy involves taking a person's own immune cells and modifying them to fight cancer cells when infused back into the body.

ThermoGenesis, now a wholly owned subsidiary of Cesca Therapeutics, develops automated medical devices and technologies for cell-based therapies. Cesca will report ThermoGenesis as a completely owned device division in the first quarter 2019 financial results.

In connection with the reorganization, Haihong Zhu, president of ThermoGenesis, has been appointed president of CARTXpress Bio.

The reorganization and share exchange took effect Jan. 1.